Day 2 Recap: The Governance Roots of the US Healthcare Crisis

CONTENTS

The second day of the symposium highlighted how top-down healthcare interventions are often blind to what individual patients, physicians, or hospitals need, discussed the nuances between healthcare systems in different countries, and ultimately championed market-based models and competition as the solutions to the governance crisis. 

Knowledge all the way down 

A recurrent theme on the second day was Austrian economist F.A. Hayek’s knowledge problem. Knowledge of what works for oneself as a patient or for healthcare as a physician or provider is dispersed among multiple people (since knowledge often constitutes their personal experiences) and across time and space in their existence. As such, no individual agent or institution knows the particular circumstances of life experiences and commands such knowledge since such an institutional agent would have to be simultaneously present in the lives of multiple people. The result is that centralized decision-makers make decisions that either do not benefit or actively harm patient health, consumer choice, and physician practice. 

The problem came into full focus with the government’s decisions on insulin coverage, as noted by the first speaker. Moiz Bhai presented on behalf of himself and co-author William Watson (both from the University of Arkansas). Their research paper examined the effects of the Medicare Advantage insulin copay cap ($35) introduced under the Inflation Reduction Act on utilization, adherence, and health outcomes among Medicare Advantage enrollees. 

Their finding was that the measure either did not apply or did not work. The copay cap did not apply to most Medicare Advantage enrollees, as the average copay was already below $35 before the policy. Moreover, when it did apply, the cap was largely decorative, functioning as a pure financial transfer (~$99/year to affected patients) rather than meaningfully improving health outcomes or adherence. This should not be surprising if we look at what people actually need: as the presenter and discussants pointed out, demand for insulin among diabetics is largely inelastic (they need it to survive, after all), meaning price reductions do not significantly change insulin use. 

The next paper by Emil Panzaru et al., Research Director at the Consumer Choice Center, made an explicit case for the knowledge problem, arguing from a Hayekian perspective against a neo-Brandeisian approach to antitrust regulation of US hospital mergers and in favor of the consumer welfare standard. Neo-Brandeisians mischaracterize the consumer welfare standard as grounded in utility-maximization and perfect-competition models; the real debate is epistemic and practical, not about what domination means or whether domination might be a problem. Lawmakers and policymakers lack the knowledge to determine whether a hospital merger constitutes domination, nor do they know that the issue is driven by concentration rather than other factors such as bargaining power.  Empirical studies on hospital mergers fail to establish clean causal estimates; structural measures such as the HHI index do not reliably track the harms that neo-Brandeisians claim to identify. The consumer welfare standard, grounded in simple universal rules, is preferable because it minimizes the knowledge burdens on regulators and reduces arbitrary political interference. 

Different healthcare systems make a difference

The third presentation by Brittany La Couture (Vice President for Health Policy at Applied Policy) and Jim Scott (President and CEO of Applied Policy) highlighted shortcomings in US drug pricing and argued that any attempt to fix the issue via Most-Favored-Nation pricing would do more harm than good both to the US and to European countries. The GLOBE, GUARD, and GENEROUS models that make up MFN pricing apply to only 25% of the fee-for-service Medicare population, meaning fewer than 10 million of the 60+ million Medicare beneficiaries are actually affected. Moreover, projected savings collapsed from ~$12 billion to ~$440 million largely due to pharmaceutical companies signing White House deals to participate in GENEROUS in exchange for exemption from GLOBE. 

On the other hand, international reference pricing creates a global chain reaction: drug companies are already withdrawing from or delaying launches in markets like Denmark and the UK to avoid creating low reference prices that would affect U.S. reimbursement caps. Amgen withdrew Repatha from Denmark; AstraZeneca postponed new UK launches citing MFN policy uncertainty. 

Finally, the effect can rebound to the US’s detriment. At the same time as the MFN was rolled out, Germany proposed clawing back pharmaceutical discounts to offset health insurance fund deficits, compounding political friction between the two countries. In response, the United States Trade Representative launched a Section 301 investigation into German pharmaceutical pricing practices. Symposium chair and CCC Managing Director Fred Roeder testified in the hearing, warning that the use of government-imposed drug prices from Europe would stifle innovation in the world’s largest pharmaceutical market, and provided first-hand feedback.  

The fourth and final presentation of the day was by Trisha Singh (MPA, Health Policy and Management, NYU Wagner), who joined the conference online from New York to discuss her paper on reforming Medicare’s payment governance through direct, risk-adjusted cash transfers to patients. Comparisons were drawn with Germany’s sickness fund model and the United Kingdom’s NHS, though the panel agreed these are fraught with difficulties. Our Fred Roeder correctly pointed out that German funds have minimal real differentiation and that German cashback mechanisms previously were ultimately abandoned, as well as the fact that the NHS has limited applicability to America given highly integrated provider structure and limited private provision. 

Consumer choice and market innovation remain key 

Regardless of the paper, the group returned to the same conclusion: market-based alternatives driven by consumer choice and unleashed innovation were sorely needed in US healthcare. When it came to the first paper, a broader market shift toward GLP-1 medications is occurring, making the insulin copay cap increasingly backward-looking as a policy intervention. Concerning the second paper, private property, price signals, and profit-and-loss mechanisms allow decentralized knowledge to coordinate healthcare delivery more effectively than regulators can. The broader takeaway from the MFN discussion was that the U.S. drug pricing system is faulty, but reference pricing imports a flawed solution that doesn’t address root causes — domestic regulatory reform, hospital and physician pricing, and market-based structures would be more effective. 

The second day concluded with thanks to all participants for their contributions and by planning for further engagement based on the symposium papers. Expect SSRN previews of the papers and op-ed media engagement in the next few weeks.

Related Issues

Your support helps us defend consumer choice worldwide.